Breaking News Instant updates and real-time market news.

INCY

Incyte

$97.83

3.05 (3.22%)

, MRK

Merck

$62.77

0.11 (0.18%)

08:52
10/10/16
10/10
08:52
10/10/16
08:52

Incyte treatment looking 'promising,' says JMP Securities

After reviewing recent data, JMP Securities analyst Liisa Bayko says that the combination of Incyte's (INCY) Epacadostat plus Merck's (MRK) Keytruda is "emerging as a promising treatment, potentially even best in class." The analyst says that the progression free survival rate of the combination in melanoma patients "is emerging to be quite competitive," while the efficacy rate in other solid tumors "seemed encouraging." The analyst raised her price target on Incyte to $110 from $100 and keeps an Outperform rating on the stock.

INCY

Incyte

$97.83

3.05 (3.22%)

MRK

Merck

$62.77

0.11 (0.18%)

  • 10

    Oct

  • 25

    Oct

  • 06

    Nov

INCY Incyte
$97.83

3.05 (3.22%)

10/06/16
LEHM
10/06/16
DOWNGRADE
Target $50
LEHM
Equal Weight
Alnylam downgraded to Equal Weight from Overweight at Barclays
Barclays analyst Geoff Meacham downgraded Alnylam Pharmaceuticals (ALNY) to Equal Weight saying he views other SMid cap biotech names as more attractive following the company's recent pipeline setbacks. The analyst removed Revusiran sales from his Alnylam model after the program was discontinued yesterday and he cut his price target for the shares to $50 from $85. Meacham lists Neurocrine (NBIX), Prothena (PTRA) and Incyte (INCY) as names he finds more attractive over the next 12 months. Alnylam is trading down 44% in pre-market trading to $39.25.
10/07/16
GSCO
10/07/16
NO CHANGE
GSCO
Smid-cap Biotech sector upgraded to Attractive from Neutral at Goldman
Goldman analyst Salveen Richter upgraded the Smid-cap biotechnology to Attractive and said he favors and companies with near-term pipeline data or regulatory events where he has conviction.Names he recommends are Buy rated BioMarin (BMRN), bluebird bio (BLUE), GW Pharma (GWPH), Incyte (INCY), Kite (KITE), and Sage (SAGE).
10/07/16
LEER
10/07/16
NO CHANGE
LEER
Outperform
Incyte Epacadostat Phase 1 Melanoma data maturing well, says Leerink
Leerink analyst Michael Schmidt says the data from ECHO-202 Phase 1 study evaluating the combination of Incyte's (INCY) IDO1 inhibitor epacadostat with Merck's (MRK) Keytruda confirms the previously published results and appears to be maturing well. The analyst reiterates an Outperform rating on Incyte's shares, saying Jakafi remains a compelling long-term growth driver for the company, expectations for baricitinib are still moderate, and its maturing oncology pipeline of 14 molecules including epacadostat represents a long-term value driver.
10/07/16
BMOC
10/07/16
NO CHANGE
Target $121
BMOC
Outperform
Incyte price target raised to $121 from $100 at BMO Capital
BMO Capital analyst Ian Somaiya raised his price target for Incyte to $121 citing an increased probability of success for epacadostat with Keytruda in metastatic melanoma following today's data. The analyst raised his probability and success to 80% from 50% and keeps an Outperform rating on Incyte.
MRK Merck
$62.77

0.11 (0.18%)

10/10/16
LEER
10/10/16
NO CHANGE
LEER
Outperform
Leerink sees Bristol-Myers sliding after Merck's 'spectacular' Keytruda data
Leerink analyst Seamus Fernandez said Bristol-Myers' (BMY) Checkmate-026 data presented at the European Society of Medical Oncology meeting was disappointing, noting there was no signal of benefit on progression-free survival or overall survival and only "modest differentiation" on response rate in the 88 patients with PDL1 biomarker positivity greater than or equal to 50%. Meanwhile, Merck (MRK) presented "spectacular" data for Keytruda monotherapy at the meeting, said Fernandez, who expects Bristol shares to be down "significantly" today in light of the meeting presentations. The analyst, who still thinks Bristol has a significant opportunity to compete with Merck's Keytruda in the PDL1 high portion of the market, keeps an Outperform rating on Bristol shares, which are down nearly 6% in pre-market trading.
10/10/16
BMOC
10/10/16
NO CHANGE
BMOC
Merck should strengthen leadership in first line NSCLC, says BMO Capital
BMO Capital analyst Alex Arfaei says that upcoming data should strengthen Merck's (MRK) lead in 1L NSCLC. The analyst adds that the data could support off-label use of Merck's Keytruda in additional 1L NSCLC patients, and he says that the data "should be negative" for Bristol-Myers' (BMY) Opdivo drug. Arfaei keeps an Outperform rating on Merck and a Market Perform rating on Bristol-Myers.
10/10/16
LEER
10/10/16
NO CHANGE
LEER
Market Perform
Merck 'steals the show' at ESMO with Keytruda data, says Leerink
Leerink analyst Seamus Fernandez said Merck (MRK) stole the show at ESMO with its Keytruda data and he continues to think the company will dominate first line lung cancer treatment for years to come in patients with 50%+ PDL1 expression. Additionally, he expects Merck to gain additional traction in the overall market, noting that confirmation that Keytruda is benefiting patients when combined with Alimta/carboplatin with Alimta maintenance raises the possibility Merck could compete broadly in the overall non-squamous patient population. However, Fernandez keeps a Market Perform rating on Merck, as he thinks its current valuation largely reflects improved growth prospects through 2020.

TODAY'S FREE FLY STORIES

MUX

McEwen Mining

$2.21

-0.225 (-9.26%)

11:30
09/19/17
09/19
11:30
09/19/17
11:30
Options
Call writer opens the largest open interest block in McEwen Mining options »

Call writer opens the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAL

American Airlines

$45.31

-0.69 (-1.50%)

11:25
09/19/17
09/19
11:25
09/19/17
11:25
Options
American Airlines call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

HQY

HealthEquity

$45.77

0.65 (1.44%)

11:25
09/19/17
09/19
11:25
09/19/17
11:25
Conference/Events
HealthEquity participates in a conference call with Chardan »

Conference call with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 25

    Sep

NHI

National Health Investors

$79.82

-0.175 (-0.22%)

11:25
09/19/17
09/19
11:25
09/19/17
11:25
Conference/Events
National Health Investors to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

OPXA

Opexa Therapeutics

$1.09

0.07 (6.86%)

11:25
09/19/17
09/19
11:25
09/19/17
11:25
Conference/Events
Opexa Therapeutics to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

JKS

JinkoSolar

$27.78

0.14 (0.51%)

, JASO

JA Solar

$8.14

0.25 (3.17%)

11:21
09/19/17
09/19
11:21
09/19/17
11:21
Periodicals
EU eases trade restrictions on Chinese solar panels, People's Daily reports »

China has welcomed the…

JKS

JinkoSolar

$27.78

0.14 (0.51%)

JASO

JA Solar

$8.14

0.25 (3.17%)

CSIQ

Canadian Solar

$16.80

-0.47 (-2.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NUVA

NuVasive

$57.80

-0.68 (-1.16%)

, EFII

Electronics for Imaging

$41.56

-0.03 (-0.07%)

11:21
09/19/17
09/19
11:21
09/19/17
11:21
Hot Stocks
NuVasive slides as GlassHouse Research sees 'profusion of accounting red flags' »

GlassHouse Research noted…

NUVA

NuVasive

$57.80

-0.68 (-1.16%)

EFII

Electronics for Imaging

$41.56

-0.03 (-0.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 20

    Sep

  • 21

    Sep

$NSD

NASDAQ Market Internals

11:17
09/19/17
09/19
11:17
09/19/17
11:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AIR

AAR Corp.

$36.87

0.32 (0.88%)

11:16
09/19/17
09/19
11:16
09/19/17
11:16
Hot Stocks
AAR Corp. to acquire two MRO facilities from Premier Aviation »

AAR announced that it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

$NYE

NYSE Market Internals

11:16
09/19/17
09/19
11:16
09/19/17
11:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:15
09/19/17
09/19
11:15
09/19/17
11:15
General news
Breaking General news story  »

4-Week Bill Auction to be…

BBY

Best Buy

$52.43

-4.92 (-8.58%)

11:13
09/19/17
09/19
11:13
09/19/17
11:13
Technical Analysis
Technical View: Best Buy falls to session lows following outlook »

The shares have been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

SIEGY

Siemens

$69.98

0.26 (0.37%)

11:11
09/19/17
09/19
11:11
09/19/17
11:11
Hot Stocks
Siemens, PAS announce partnership to provide monitoring for control systems »

Siemens and PAS Global…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UAL

United Continental

$58.51

0.395 (0.68%)

11:10
09/19/17
09/19
11:10
09/19/17
11:10
Options
Repeat of bullish option activity in UAL »

Repeat of bullish option…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

VIAB

Viacom

$27.32

-0.35 (-1.26%)

, DISCA

Discovery

$21.32

-0.62 (-2.83%)

11:08
09/19/17
09/19
11:08
09/19/17
11:08
Hot Stocks
Cowen sees more trouble ahead for traditional TV names »

Research firm Cowen cut…

VIAB

Viacom

$27.32

-0.35 (-1.26%)

DISCA

Discovery

$21.32

-0.62 (-2.83%)

FOXA

21st Century Fox

$26.50

-0.55 (-2.03%)

DIS

Disney

$98.43

0.325 (0.33%)

CBS

CBS

$57.71

-0.01 (-0.02%)

GOOGL

Alphabet Class A

$929.75

-5.54 (-0.59%)

GOOG

Alphabet

$915.00

-5.29 (-0.57%)

FB

Facebook

$170.01

-1.63 (-0.95%)

NFLX

Netflix

$184.62

2.27 (1.24%)

AMZN

Amazon.com

$974.19

-12.6 (-1.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

  • 28

    Sep

  • 02

    Oct

  • 16

    Oct

  • 29

    Nov

XON

Intrexon

$19.19

-0.28 (-1.44%)

11:07
09/19/17
09/19
11:07
09/19/17
11:07
Hot Stocks
Intrexon's Oxitec plans to build centralized mosquito egg production unit »

Oxitec, a wholly owned…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRCM

Care.com

$14.45

-0.14 (-0.96%)

11:04
09/19/17
09/19
11:04
09/19/17
11:04
Hot Stocks
Care.com names George Bell to board as lead independent director »

Care.com yesterday…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MTB

M&T Bank

$152.67

1 (0.66%)

11:03
09/19/17
09/19
11:03
09/19/17
11:03
Hot Stocks
M&T Bank enters community-focused strategic partnership with NY Jets »

The New York Jets and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNC

Centene

$88.33

-6.25 (-6.61%)

11:02
09/19/17
09/19
11:02
09/19/17
11:02
Hot Stocks
Coordinated Care awarded Commendable Accreditation status from NCQA »

Coordinated Care, a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 27

    Sep

  • 24

    Oct

USB

U.S. Bancorp

$52.64

0.255 (0.49%)

11:01
09/19/17
09/19
11:01
09/19/17
11:01
Hot Stocks
U.S. Bancorp boosts quarterly dividend by 7% to 30c »

U.S. Bancorp said its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 17

    Jan

NUVA

NuVasive

$57.80

-0.68 (-1.16%)

11:01
09/19/17
09/19
11:01
09/19/17
11:01
Periodicals
NuVasive mentioned cautiously in short report from GlassHouse Research 

Reference Link

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RGC

Regal Entertainment

$16.08

-0.365 (-2.22%)

11:00
09/19/17
09/19
11:00
09/19/17
11:00
Conference/Events
Regal Entertainment management to meet with MKM Partners »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 28

    Sep

  • 02

    Oct

T

AT&T

$37.94

0.515 (1.38%)

11:00
09/19/17
09/19
11:00
09/19/17
11:00
Options
AT&T option volume double normal as implied volatility term structure inverts »

AT&T option volume…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

KR

Kroger

$21.32

-0.12 (-0.56%)

10:59
09/19/17
09/19
10:59
09/19/17
10:59
Hot Stocks
Kroger outlook revised to Negative from Stable by Fitch »

Fitch affirmed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Oct

  • 30

    Nov

TSLA

Tesla

$385.00

5.19 (1.37%)

10:58
09/19/17
09/19
10:58
09/19/17
10:58
Conference/Events
Tesla management to meet with MKM Partners »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 19

    Sep

  • 02

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.